Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2025-17 - Agalsidase beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2027 · 307 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-17 -Agalsidase beta

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

The procedure is explicitly not a procurement under EU/German procurement law. Legal remedies are via social courts, wh...

No estimated value, no volume guarantees. Discount agreements may be unattractive if volumes are low.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Agalsidase beta to the participating health insurance funds under discount agreements.
  • Open House procedure with no exclusivity and no negotiation.
Afficher le résumé complet

This is an Open House procedure for Rabattverträge (discount agreements) under §130a SGB V for the active ingredient Agalsidase beta. The lead buyer is Techniker Krankenkasse (TK) in cooperation with HEK and hkk. The contract is a non-exclusive framework without negotiation; no estimated value is provided. The deadline for submission is 2027-06-29, but contributions are possible at any time during the contract period (01.07.2025-30.06.2027). Only one lot is identified. The opportunity is open to all qualified pharmaceutical entrepreneurs who meet the eligibility criteria. The notice explicitly states this is not a public procurement subject to procurement law, and legal challenges go to social courts. No procurement documents were analyzed (only the XML notice).

Risques

The procedure is explicitly not a procurement under EU/German procurement law. Legal remedies are via social courts, wh...

No estimated value, no volume guarantees. Discount agreements may be unattractive if volumes are low.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG with a valid marketing authorization for Agalsidase beta.
  • Registered seat in Germany, EU, or EEA (§9(2) AMG).

Eligibility

  • No criminal convictions or exclusion grounds (GWB §§123,124).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; contract is offered to all eligible participants without competitive award.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-17 - Agalsidase beta

Conclusion of pharmaceutical discount agreements for the active substance Agalsidase beta under the Open House procedure. No exclusivity, no negotiation, uniform conditions. Contract term 24 months (01.07.2025-30.06.2027).

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; contract is offered to all eligible participants without competitive award.

Date limite

Deadline Jun 29, 2027

Détails de la procédure

Date de publication
25 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
336062-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3